Anti-fibrotic treatment in patients with idiopathic pulmonary fibrosis:A cohort study

Anti-fibrotic treatment in patients with idiopathic pulmonary fibrosis:A cohort study - Anti-fibrotic treatment in patients with IPF:A cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020392

Enrollment

100

Registered

2015-12-29

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Satisfy the diagnostic criteria of IPF. 2) Anti fibroticc agents (pirfenidone or nintedanib) are administered. 3) Written informed consent.

Exclusion criteria

Exclusion criteria: without patients' consent

Design outcomes

Primary

Measure	Time frame
The primary outcome was the association between anti fibrosis agents (pirfenidone and nintedanib) and survival in patients with IPF.	—

Secondary

Measure	Time frame
Other secondary outcomes included effect of pressure in the pulmonary circulation,response to inflammatory cytokine, miRNA, quality of life, and association between baseline patient characteristics and survival.	—

Countries

Japan

Contacts

Public Contactkeishi Oda

University of Occupational and Environmental Health, Japan Department of Respiratory Medicine

oda-keishi@med.uoeh-u.ac.jp093-691-7453

Outcome results